SITAZIT D 100/10 TABLET is used to manage type II diabetes mellitus which is inadequately controlled on metformin monotherapy. It is a combination of Dapagliflozin and Sitagliptin which belongs to the group of medicines called Antidiabetic agents. It effectively controls blood sugar levels where dapagliflozin inhibits SGLT2, increasing urinary glucose excretion and reducing blood levels of glucose and Sitagliptin inhibits DPP-4, increases glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting in increased insulin synthesis and decreased glucagon release.

SITAZIT D 100/10 TABLET is not recommended for use in patients having severe kidney problems or those on dialysis. Before taking the medicine, inform your doctor if you have inflammation of the pancreas, gallstones, alcohol dependence, or very high levels of triglycerides in the blood or any heart, kidney or liver problems. It should be used in pregnant women only if considered clearly necessary. It should be used with caution in breastfeeding women. Safety and effectiveness of SITAZIT D 100/10 TABLET in children and adolescents (under 18 years of age) have not been established.

It is important to stay on the diet and exercise recommended by your doctor while taking SITAZIT D 100/10 TABLET as it can help the body use its blood sugar better. The most common side effects are headache, flatulence and constipation. Consult your doctor if any of the side effects worsen or persist for a longer period of time.